Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation
November 24, 2026

Notice Regarding Cancellation of Treasury Shares

(Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act of Japan)

Alfresa Holdings Corporation hereby announces that, at a meeting of its Board of Directors held on November 24, 2026, it resolved to cancel treasury shares pursuant to Article 178 of the Companies Act of Japan, as outlined below.

1.	Type of shares to be canceled	Common stock
2.	Number of shares to be canceled	6,800,000 shares (3.55% of the number of issued shares before the cancellation)
3.	Scheduled date of cancellation	December 10, 2026

(Reference)

The percentage of treasury shares held after the cancellation is expected to be 4.72% of the number of issued shares after the cancellation.*

Number of issued shares after the cancellation	184,500,000 shares
Number of treasury shares after the cancellation	8,703,719 shares

* The calculation is based on the number of shares as of November 20, 2026. The 477,745 shares held by the Board Incentive Plan trust are not included in the treasury shares.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its mission, "we create and deliver a fresh life for all," come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, regenerative medicine-related business, and CRO business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026. For more information, please see: https://www.alfresa.com/eng/